The Role of Interferon in Picornavirus Infections

  • Ferdinando Dianzani
  • Maria R. Capobianchi
  • Donatella Matteucci
  • Mauro Bendinelli
Part of the Infectious Agents and Pathogenesis book series (IAPA)


Interferons (IFN) are at least three types of functionally related proteins that are newly produced and secreted by cells stimulated with an inducer. Besides viruses, a number of substances are capable of inducing IFN in vivo and in vitro, including bacterial endotoxin, natural and synthetic RNAs, polysaccharides, polyanions, and mitogens.


Newcastle Disease Virus Encephalomyocarditis Virus Antiviral State CVB3 Infection Human Lymphoid Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baron, S., Dianzani, F., and Stanton, J. (eds.), 1981–1982, The interferon system: A review to 1982, Texas Rep. Biol. Med. 41:1–715.Google Scholar
  2. 2.
    Baron, S., Buckler, C. E., McCloskey, R. V., and Kirschstein, R. L., 1966, Role of interferon during viremia. I. Production of circulating interferon,J. Immunol. 96:12 – 16.PubMedGoogle Scholar
  3. 3.
    Baron, S., Buckler, C. E., Friedman, R., and McCloskey, R., 1966, Role of interferon during viremia. II. Protective action of circulating interferon,J. Immunol. 96:17–24.PubMedGoogle Scholar
  4. 4.
    Dianzani, F., Rita, G., Cantagalli, P., and Gagnoni, S., 1969, Effect of DEAE-dextran on interferon production and protective effect in mice treated with the double-stranded polynucleotide complex polyinosinic-polycytidylic acid, J. Immunol. 102:24 – 27.PubMedGoogle Scholar
  5. 5.
    Gresser, I., Bourali, C., Thomas, M. T., and Falcoff, E., 1968, Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus, Proc. Sco. Exp. Biol. Med. 127:491–496.Google Scholar
  6. 6.
    Gresser, I., Tovey, M. G., Bandu, M. T., Maury, C., and Brouty-Boyé, D., 1976, Role of interferon in the pathogenesis of virus disease in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection.J. Exp. Med. 144:1305–1315.PubMedCrossRefGoogle Scholar
  7. 7.
    Giron, D. J., Liu, R. Y., Hemphill, F. E., Pindak, F. F., and Schmidt, J. P., 1980, Role of interferon in the antiviral state elicited by selected interferon inducers, Proc. Soc. Exp. Biol. Med. 163:146–150.PubMedGoogle Scholar
  8. 8.
    Norris, D., and Loh, P. C., 1973, Coxsackievirus myocarditis: Prophylaxis and therapy with an interferon stimulator, Proc. Soc. Exp. Biol. Med. 142:133–136.PubMedGoogle Scholar
  9. 9.
    Olsen, G. A., Kern, E. R., Glasgow, L. A., and Overall, J. C. Jr., 1976, Effect of treatment with exogenous interferon polyinosinic acid-polycytidylic acid, or poly-inosinic acid-polycytidylic acid-poly-L-lysine complex on encephalomyocarditis virus infections in mice, Antimicrob. Agents Chemother. 10:668–676.PubMedGoogle Scholar
  10. 10.
    Shalaby, M. R., Hamilton, E. B., Benninger, A. H., and Marafino, B.J. Jr., 1985, In vivo antiviral activity of recombinant murine gamma interferon, J. Interferon Res. 5:339–345.PubMedCrossRefGoogle Scholar
  11. 11.
    Dianzani, F., Viano, I., Santiano, M., Zucca, M., and Baron, S., 1977, Effect of cell density on development of the antiviral state in interferon-producing cells: A possible model of in vivo conditions, Proc. Soc. Exp. Biol. Med. 155:445–448.PubMedGoogle Scholar
  12. 12.
    Dianzani, F., Gullino, P., and Baron, S., 1978, Rapid activation of the interferon system in vivo, Infect. Immun. 20:55–57.PubMedGoogle Scholar
  13. 13.
    Simon, E. H., Kung, S., Koh, T. T., and Brandman, P., 1976, Interferon-sensitive mutants of mengovirus. I. Isolation and biological characterization, Virology 69:727–736.PubMedCrossRefGoogle Scholar
  14. 14.
    Marcus, P. I., Guidon, P. T. Jr., and Sekellick, M. J., 1981, Interferon induction by viruses. VII. Mengovirus: “Interferon-sensitive” mutant phenotype attributed to in-terferon-inducing particle activity,J. Interferon Res. 1:601–611.PubMedCrossRefGoogle Scholar
  15. 15.
    Fleischmann, W. R., Jr., 1977, Priming of interferon action, Tex. Rep. Biol. Med. 35:316–325.PubMedGoogle Scholar
  16. 16.
    Cohen, S. H., Bolton, V., and Jordan, G. W., 1983, Relationship of interferon-induc-ing particle phenotype to encephalomyocarditis virus-induced diabetes mellitus, Infect. Immun. 42:605–611.PubMedGoogle Scholar
  17. 17.
    Yoon, J. W., Cha, C. Y., and Jordan, G. W., 1983, The role of interferon in virus-induced diabetes,J. Infect. Dis. 147:155–159.PubMedCrossRefGoogle Scholar
  18. 18.
    Gould, C. L., McMannama, K. G., Bigley, N.J., and Giron, D. J., 1985, Exacerbation of the pathogenesis of the diabetogenic variant of encephalomyocarditis virus in mice by interferon,J. Interferon Res. 5:33–37.PubMedCrossRefGoogle Scholar
  19. 19.
    Lutton, C. W., and Gauntt, G. J., 1985, Ameliorating effect of IFN-beta and anti-IFN-beta on coxsackievirus B3-induced myocarditis in mice,J. Interferon Res. 5:137–146.PubMedCrossRefGoogle Scholar
  20. 20.
    Chany, C., and Cerutti, I., 1977, Enhancement of antiviral protection against encephalomyocarditis virus by a combination of isoprinosine and interferon, Arch. Virol. 55:225–231.PubMedCrossRefGoogle Scholar
  21. 21.
    Stebbing, N., Dawson, K. M., and Lindley, I. J. D., 1978, Requirement for macrophages for interferon to be effective against encephalomyocarditis virus infection of mice, Infect. Immun. 19:5–11.PubMedGoogle Scholar
  22. 22.
    Belardelli, F., Vignaux, F., Proietti, E., and Gresser, I., 1984, Infection of mice with antibody to interferon renders peritoneal macrophages permissive for vesicular stomatitis virus and encephalomyocarditis virus, Proc. Natl. Acad. Sci. USA 81:602–606.PubMedCrossRefGoogle Scholar
  23. 23.
    Maheshwari, R. K., Husain, M. M., Attallah, A. M., and Friedman, R. M., 1983, Tunicamycin treatment inhibits the antiviral activity of interferon in mice, Infect. Immun. 41:61–66.PubMedGoogle Scholar
  24. 24.
    Klein, A. S., Fixier, R., and Shoham, J., 1984, Antiviral activity of a thymic factor in experimental viral infections. I. Thymic hormonal effect on survival, interferon production and NK cell activity in mengo virus infected mice,J. Immunol. 132:3159–3163.PubMedGoogle Scholar
  25. 25.
    Cho, C. T., Feng, K. K., McCarthy, V. P., and Lenahan, M. F., 1982, Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer, Infect. Immun. 37:720–727.PubMedGoogle Scholar
  26. 26.
    Sasaki, O., Karaki, T., and Imanishi, J., 1986, Protective effect of interferon on infections with hand, foot and mouth disease virus in newborn mice,J. Infect. Dis. 153:498–502.PubMedCrossRefGoogle Scholar
  27. 27.
    Mims, C. A., and White, D. O., 1984, Viral Pathogenesis and Immunology, Blackwell Scientific Publications, Oxford.Google Scholar
  28. 28.
    Faden, H., Glasgow, L. A., and Overall, J. C. Jr., 1978, Variable effect of encepha-lomyocarditis virus on host defense mechanisms, Infect. Immun. 19:94–100.PubMedGoogle Scholar
  29. 29.
    Stringfellow, D. A., Kern, E. R., Kelsey, D. K., and Glasgow, L. A., 1977, Suppressed response to interferon induction in mice infected with encephalomyocarditis virus, semliki Forest virus, influenza A2 virus, herpesvirus hominis type 2 or murine cytomegalovirus,J. Infect. Dis. 135:540–551.PubMedCrossRefGoogle Scholar
  30. 30.
    Rytel, M. W., 1969, Interferon response during Coxsackie B-3 infection in mice. I. The effect of cortisone,J. Infect. Dis. 120:379–382.PubMedCrossRefGoogle Scholar
  31. 31.
    Reyes, M. P., and Lerner, A. M., 1976, Interferon and neutralizing antibody in sera of exercised mice with coxsackievirus B-3 myocarditis, Proc. Soc. Exp. Biol. Med. 151:333–338.PubMedGoogle Scholar
  32. 32.
    Pozzetto, B., and Gresser, I., 1985, Role of sex and early interferon production in the susceptibility of mice to encephalomyocarditis virus,J. Gen. Virol. 66:701–709.PubMedCrossRefGoogle Scholar
  33. 33.
    Bendinelli, M., Ruschi, A., and Santopadre, G., 1965, Replicazione virale e produzione di interferone in topi a dieta carente infettati con virus mengo, Riv. liai. Igiene 25:191–204.Google Scholar
  34. 34.
    Kurane, I., Binn, L. N., Bancroft, W., and Ennis, F. A., 1985, Human lymphocyte responses to hepatitis A virus-infected cells: Interferon production analysis of infected cells,J. Immunol. 135:2140–2144.PubMedGoogle Scholar
  35. 35.
    Vallbracht, A., Gabriel, P., Zahn, J., and Flehmig, B., 1985, Hepatitis A virus infection and the interferon system,J. Infect. Dis. 152:211–213.PubMedCrossRefGoogle Scholar
  36. 36.
    Langford, M. P., Villarreal, A. L., and Stanton, G. J., 1983, Antibody and interferon act synergistically to inhibit enterovirus, adenovirus and herpes simplex virus infection, Infect. Immun. 41:214–218.PubMedGoogle Scholar
  37. 37.
    Jordan, G. W., and Bolton, V., 1985, Interferon-sensitive coxsackievirus variants in nature,J. Interferon Res. 5:289–296.PubMedCrossRefGoogle Scholar
  38. 38.
    Matteucci, D., Paglianti, M., Giangregorio, A. M., Capobianchi, M. R., Dianzani, F., and Bendinelli, M., 1985, Group B coxsackieviruses readily establish persistent infections in human lymphoid cell lines,J. Virol. 56:651–654.PubMedGoogle Scholar
  39. 39.
    Kandolf, R., Canu, A., and Hofschneider, P. H., 1985, Coxsackievirus B3 can replicate in cultured human foetal heart cells and is inhibited by interferon,J. Mol. Cell. Cardiol. 17:167–198.PubMedCrossRefGoogle Scholar
  40. 40.
    Bendinelli, M., Matteucci, D., Conaldi, P. G., Giangregorio, A. M., Capobianchi, M. R., and Dianzani, F., 1988, Mechanisms of group B coxsackievirus persistence in human cells, Eur. Heart J. 7 (suppl. E):(in press).Google Scholar
  41. 41.
    Langford, M. P., Barber, J. C., Sklar, V. E. F., Clark, S. W. III, Patriarca, P. A., Onarato, I. M., Yin-Murphy, M., and Stanton, G. J., 1985, Virus-specific, early appearing neutralizing activity and interferon in tears of patients with acute hemorrhagic conjunctivitis, Curr. Eye Res. 4:233–239.PubMedCrossRefGoogle Scholar
  42. 42.
    Vaquero, C., Aujean-Rigaud, O., Sanceau, J., and Falcoff, E., 1981, Effect of interferon on transient shut-off of cellular RNA and protein synthesis induced by mengo virus infection, Antiviral Res. 1:123–134.PubMedCrossRefGoogle Scholar
  43. 43.
    Nilsen, T. W., and Baglioni, C., 1979, Mechanisms for discrimination between viral and host mRNA in interferon-7 treated cells, Proc. Natl. Acad. Sci. USA 76:2600–2604.PubMedCrossRefGoogle Scholar
  44. 44.
    Merigan, T. C., Hall, T. S., Reed, S. E., and Tyrrel, D. A. J., 1973, Inhibition of respiratory virus infection by locally applied interferon, Lancet 1:563–567.PubMedCrossRefGoogle Scholar
  45. 45.
    Couch, R. B., 1984, The common cold: control?,J. Infect. Dis. 150:167–173.PubMedCrossRefGoogle Scholar
  46. 46.
    Isaacs, D., Clarke, J. R., Tyrrel, D. A. J., Webster, A. D. B., and Valman, H. B., 1981, Deficient production of leukocyte interferon (interferon-alpha) in vitro and in vivo in children with recurrent respiratory tract infections, Lancet 31:950–952.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Ferdinando Dianzani
    • 1
  • Maria R. Capobianchi
    • 1
  • Donatella Matteucci
    • 2
  • Mauro Bendinelli
    • 2
  1. 1.Institute of VirologyUniversity of RomeRomeItaly
  2. 2.Institute of Epidemiology, Hygiene and VirologyUniversity of PisaPisaItaly

Personalised recommendations